- Home
- PRK vs TARS Comparison
PRK vs TARS Comparison
Compare PRK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRK | TARS |
|---|---|---|
| Founded | 1908 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRK | TARS |
|---|---|---|
| Price | $174.61 | $60.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $181.50 | $77.13 |
| AVG Volume (30 Days) | 63.7K | ★ 557.0K |
| Earning Date | 01-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 11.11 | N/A |
| Revenue | ★ $545,704,000.00 | $366,100,000.00 |
| Revenue This Year | $15.87 | $147.71 |
| Revenue Next Year | $7.86 | $53.74 |
| P/E Ratio | $15.72 | ★ N/A |
| Revenue Growth | 7.83 | ★ 182.44 |
| 52 Week Low | $137.97 | $38.51 |
| 52 Week High | $179.48 | $85.25 |
Technical Indicators
Market Signals| Indicator | PRK | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 29.69 |
| Support Level | $169.82 | $61.67 |
| Resistance Level | $178.49 | $67.70 |
| Average True Range (ATR) | 4.05 | 3.30 |
| MACD | 0.47 | -0.02 |
| Stochastic Oscillator | 80.45 | 2.68 |
Price Performance
Historical ComparisonAbout PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.